BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gui CP, Wei JH, Chen YH, Fu LM, Tang YM, Cao JZ, Chen W, Luo JH. A new thinking: extended application of genomic selection to screen multiomics data for development of novel hypoxia-immune biomarkers and target therapy of clear cell renal cell carcinoma. Brief Bioinform 2021:bbab173. [PMID: 34237133 DOI: 10.1093/bib/bbab173] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]
Number Citing Articles
1 Zhang W, Lyu P, Andreev D, Jia Y, Zhang F, Bozec A. Hypoxia-immune-related microenvironment prognostic signature for osteosarcoma. Front Cell Dev Biol 2022;10:974851. [PMID: 36578780 DOI: 10.3389/fcell.2022.974851] [Reference Citation Analysis]
2 Zheng X, Jiang K, Xiao W, Zeng D, Peng W, Bai J, Chen X, Li P, Zhang L, Zheng X, Miao Q, Wang H, Wu S, Xu Y, Xu H, Li C, Li L, Gao X, Zheng S, Li J, Wang D, Zhou Z, Xia X, Yang S, Li Y, Cui Z, Zhang Q, Chen L, Lin X, Lin G. CD8+ T cell/cancer-associated fibroblast ratio stratifies prognostic and predictive responses to immunotherapy across multiple cancer types. Front Immunol 2022;13. [DOI: 10.3389/fimmu.2022.974265] [Reference Citation Analysis]
3 Bao N, Zhang P, Zhu Y, Du P, Jin G, Wu B, Ding T. miR-378a-3p promotes renal cell carcinoma proliferation, migration, and invasion by targeting TOB2. Clin Transl Oncol 2022. [DOI: 10.1007/s12094-022-02984-8] [Reference Citation Analysis]
4 Li Q, Xiao X, Chen B, Song G, Zeng K, Li B, Miao J, Liu C, Luan Y, Liu B. A predictive signature based on enhancer RNA associates with immune infiltration and aids treatment decision in clear cell renal cell carcinoma. Front Oncol 2022;12:964838. [DOI: 10.3389/fonc.2022.964838] [Reference Citation Analysis]
5 Dong Y, Zhao Z, Simayi M, Chen C, Xu Z, Lv D, Tang B. Transcriptome profiles of fatty acid metabolism-related genes and immune infiltrates identify hot tumors for immunotherapy in cutaneous melanoma. Front Genet 2022;13:860067. [DOI: 10.3389/fgene.2022.860067] [Reference Citation Analysis]
6 Luan L, Dai Y, Shen T, Yang C, Chen Z, Liu S, Jia J, Li Z, Fang S, Qiu H, Cheng X, Yang Z. Development of a novel hypoxia-immune–related LncRNA risk signature for predicting the prognosis and immunotherapy response of colorectal cancer. Front Immunol 2022;13:951455. [DOI: 10.3389/fimmu.2022.951455] [Reference Citation Analysis]
7 Zheng P, Zhou C, Lu L, Liu B, Ding Y. Elesclomol: a copper ionophore targeting mitochondrial metabolism for cancer therapy. J Exp Clin Cancer Res 2022;41:271. [DOI: 10.1186/s13046-022-02485-0] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
8 Tang G, Tan L, Yuan H, Yin W. Glycosylation modification patterns reveal distinct tumor metabolism and immune microenvironment landscape in lower-grade gliomas. Front Cell Dev Biol 2022;10:886989. [DOI: 10.3389/fcell.2022.886989] [Reference Citation Analysis]
9 Shi X, Niu Y, Yang Y, Wang N, Yuan M, Yang C, Dong A, Zhu H, Jia X, Xu Q. Identification of a Prognostic Model Based on Immune Cell Signatures in Clear Cell Renal Cell Carcinoma. Oxidative Medicine and Cellular Longevity 2022;2022:1-16. [DOI: 10.1155/2022/1727575] [Reference Citation Analysis]
10 Zhao Z, Liu H, Fang D, Zhou X, Zhao S, Zhang C, Ye J, Xu J. Patient stratification based on urea cycle metabolism for exploration of combination immunotherapy in colon cancer. BMC Cancer 2022;22:883. [PMID: 35962309 DOI: 10.1186/s12885-022-09958-7] [Reference Citation Analysis]
11 Chen M, Chen Z, Lin Z, Ding X, Liang T. Utilization of hypoxia-derived gene signatures to predict clinical outcomes and immune checkpoint blockade therapy responses in prostate cancer. Front Genet 2022;13:922074. [DOI: 10.3389/fgene.2022.922074] [Reference Citation Analysis]
12 Naidoo V, Perera M, Adam A. Major heritable renal cell carcinoma syndromes: novel treatment options and future perspectives. Curr Opin Urol 2022. [PMID: 35855559 DOI: 10.1097/MOU.0000000000001030] [Reference Citation Analysis]
13 Wang Y, Zheng X, Zhu G, Li N, Zhou C, Yang C, Zeng M. Crosstalk Between Metabolism and Immune Activity Reveals Four Subtypes With Therapeutic Implications in Clear Cell Renal Cell Carcinoma. Front Immunol 2022;13:861328. [DOI: 10.3389/fimmu.2022.861328] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
14 Wang S, Wei X, Ji C, Wang Y, Zhang X, Cong R, Song N. Adipogenic Transdifferentiation and Regulatory Factors Promote the Progression and the Immunotherapy Response of Renal Cell Carcinoma: Insights From Integrative Analysis. Front Oncol 2022;12:781932. [PMID: 35356208 DOI: 10.3389/fonc.2022.781932] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
15 Qiu C, Shi W, Wu H, Zou S, Li J, Wang D, Liu G, Song Z, Xu X, Hu J, Geng H. Identification of Molecular Subtypes and a Prognostic Signature Based on Inflammation-Related Genes in Colon Adenocarcinoma. Front Immunol 2021;12:769685. [PMID: 35003085 DOI: 10.3389/fimmu.2021.769685] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]